Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St futures slip as yields and oil rebound; Fed minutes in focusĀ
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Assertio Reports Second Quarter 2025 Financial Results
August 11, 2025 4:05 PM EDTSecond Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million
Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy
LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients needs, today reported financial results for the second quarter ended June 30, 2025.
Said Brendan OGrady, Chief Executive Officer, The... More



